# EDGAR Filing Document

**Accession Number:** 0001472091
**File Stem:** 0001140361-25-022212
**Filing Date:** 2025-6
**Character Count:** 12338
**Document Hash:** 6fdfb791f659ece2587c9996cede1d29
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-25-022212.hdr.sgml**: 20250611

**ACCESSION NUMBER**: 0001140361-25-022212

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20250611

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250611

**DATE AS OF CHANGE**: 20250611

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PDS Biotechnology Corp
- **CENTRAL INDEX KEY:** 0001472091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 264231384
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37568
- **FILM NUMBER:** 251040552

**BUSINESS ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540
- **BUSINESS PHONE:** 800-208-3343

**MAIL ADDRESS:**
- **STREET 1:** 303A COLLEGE ROAD EAST
- **CITY:** PRINCETON
- **STATE:** NJ
- **ZIP:** 08540

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Edge Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20090911

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### Form 8-K

#### Current Report

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### June 11, 2025
Date of Report (Date of earliest event reported)

## PDS Biotechnology Corporation
**(**Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **001-37568**<br>| **26-4231384**<br>|
| (State or other jurisdiction of incorporation) | (Commission File Number | (IRS Employer Identification No.) |

---

---

| | |
|:---|:---|
| **303A College Road East**<br>**Princeton, NJ** | **08540**<br>|
| (Address of Principal Executive Offices) | (Zip Code) |

---

<u> (800) 208-3343 </u> <br> <u> Registrant's telephone number, including area code </u> <br> (Former name or former address if changed since last report,)

Securities registered pursuant to Section 12 (b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading Symbol(s)** | **Name of each exchange on which**<br> **registered:** |
| Common Stock, par value $0.00033 per share<br>| PDSB<br>| The Nasdaq Stock Market LLC<br>|

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.02** | **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** |

---

(e) <u>Amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan</u>

PDS Biotechnology Corporation (the "Company") held its 2025 annual meeting of stockholders on June 11, 2025 (the "Annual Meeting"). As previously disclosed, on April 29, 2025, the Board of Directors of the Company adopted, subject to stockholder approval, an amendment (the "Amendment") to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Inventive Plan (the "Restated Plan"). The stockholders voted to approve the Amendment at the Annual Meeting. The Amendment authorized an additional 3,144,049 shares for issuance under the Restated Plan to increase the aggregate number of shares issuable under the Restated Plan from 6,565,535 shares to 9,709,584 shares. The Restated Plan remains unchanged in all other respects. The foregoing description of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 hereto and is incorporated by reference herein.

---

| | |
|:---|:---|
| **Item 5.07** | **Submission of Matters to a Vote of Security Holders.** |

---

At the Annual Meeting, the following proposals were submitted to the stockholders of the Company:

---

| | |
|:---|:---|
| Proposal 1: | A proposal to elect two Class A directors of the Company, Stephen Glover and Gregory Freitag, J.D., C.P.A., each to hold office until the 2028 Annual Meeting of Stockholders or until their successors shall have been duly elected and qualified. |
| Proposal 2: | A proposal to approve an amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan. |
| Proposal 3: | A proposal to ratify the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. |
| Proposal 4: | A proposal to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. |

---

For more information about the foregoing proposals, see the Company's definitive proxy statement on Schedule 14A filed with the United States Securities and Exchange Commission on April 29, 2025. Of the 45,672,851 shares of the Company's common stock entitled to vote at the Annual Meeting, 30,130,951 shares, or approximately 65.97%, were represented at the Annual Meeting in person or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such proposal is set forth below.

Proposal 1: Election of Class A Directors.

The Company's stockholders elected the following directors to serve as Class A directors until the 2028 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified. The votes regarding the election of the directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Director** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| Stephen Glover | 10,583,259 | 2,781,271 | 16,766,421 |
| Gregory Freitag, J.D., C.P.A. | 10,291,583 | 3,072,947 | 16,766,421 |

---

Proposal 2: Approval of an amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan..

The Company's stockholders voted to approve the amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.. The votes regarding this proposal were as follows:

------

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstaining** | **Broker Non-Votes** |
| 9,158,039 | 3,285,825 | 846,475 | 16,766,421 |

---

Proposal 3: Ratification of Appointment KPMG US LLP.

The Company's stockholders ratified the appointment of KPMG US LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The votes regarding this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstaining** | **Broker Non-Votes** |
| 25,594,870 | 1,494,716 | 2,967,174 | 0 |

---

---

| | |
|:---|:---|
| Proposal 4: | Approval, by non-binding advisory vote, of the compensation of the Company's named executive officers. |

---

The Company's stockholders voted to approve, by non-binding advisory vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Votes Abstaining** | **Broker Non-Votes** |
| 8,981,125 | 3,857,108 | 452,106 | 16,766,421 |

---

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **Number** | **Description** |
| [10.1+](ef20050526_ex10-1.htm) | Amendment to the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan.. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

+ Indicates management compensatory plan or arrangement.

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **PDS Biotechnology Corporation** | **PDS Biotechnology Corporation** |
| Date: June 11, 2025 | By: | /s/ Frank Bedu-Addo, Ph.D. |
|  |  | Name: Frank Bedu-Addo, Ph.D. |
|  |  | Title: President and Chief Executive Officer |

---

------

## Exhibit 10.1

------

**Exhibit 10.1**<br>

#### AMENDMENT

#### TO THE

#### THIRD AMENDED AND RESTATED PDS BIOTECHNOLOGY CORPORATION

#### 2014 EQUITY INVENTIVE PLAN

WHEREAS, PDS Biotechnology Corporation, Inc. (the "Company") maintains the Third Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan (the "Plan"); and

WHEREAS, Section 9.1 of the Plan provides that the Plan may be amended from time to time; and

WHEREAS, the Company desires to amend the Plan in certain respects;

NOW, THEREFORE, the Plan is hereby amended, effective as of the date the stockholders of the Company approve this amendment, in the following respects:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Section 5.1 of the Plan is amended to read in its entirety as follows:

"5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Share Pool</u>. Subject to adjustment as provided in this Section 5 and in Section 8 hereof, the total number of shares of Common Stock available for Awards under the Plan shall be equal to the sum of (the "Share Pool"): (i) 4,165,535 shares of Common Stock, which was the total number of shares of Common Stock authorized for issuance under the Second Amended and Restated PDS Biotechnology Corporation 2014 Equity Incentive Plan, plus (ii) 2,400,000 shares of Common Stock, which reflects the additional shares of Common Stock authorized by the Board under the Plan as of the Effective Date, plus (iii) 3,144,049 shares of Common Stock that were approved at the Company's 2025 Annual Meeting of Stockholders."

In the event of any conflict between the terms and conditions of the Plan and the terms and conditions of this Amendment, the terms and conditions of this Amendment shall prevail and control. If any term or provision of this Amendment or the application thereof to any persons or circumstances shall, to any extent, be invalid or unenforceable, the remainder of this Amendment or the application of such term or provision to persons or circumstances other than those as to which it is held invalid or unenforceable shall not be affected thereby, and each term and provision of this Amendment shall be valid and enforced to the fullest extent permitted by law.

IN WITNESS WHEREOF, the undersigned has executed this Amendment as of the date first written above on behalf of the Company.

---

| | |
|:---|:---|
| PDS BIOTECHNOLOGY CORPORATION | PDS BIOTECHNOLOGY CORPORATION |
| By:  | <u>*/s/ Frank Bedu-Addo*</u> |
| Name: Frank Bedu-Addo, Ph.D. | Name: Frank Bedu-Addo, Ph.D. |
| Title: Chief Executive Officer | Title: Chief Executive Officer |

---

------